EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted TPGS ultrasound-responsive nanodroplets modulate P-gp and mitochondria to enhance doxorubicin sensitivity in multidrug-resistant breast cancer

Ling Ge, Xiaomeng Liu, Yan Sun, Ruo Zhang, Limin Liu, Jie Li

Frontiers in Bioengineering and Biotechnology · 10.11.2026 · 14

DOI: 10.3389/fbioe.2026.1991867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 10.11.2026. Verfasst von Ling Ge und 5 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although drugs targeting mitochondria or P-gp combined with traditional chemotherapy drugs represent a novel and effective treatment for multiple drug resistance (MDR). Nevertheless, the efficacy is still restricted by several obstacles, including significant toxicity. Nanoscale drug delivery systems (DDSs) offer a favourable solution to reduce the toxicity and side effects of systemic administration. Meanwhile, DDSs provide a promising strategy to implement spatially and temporally controlled drug release when combined with ultrasound-targeted microbubble destruction (UTMD). Therefore, novel ultrasonic nanodroplets (NDs) which consist of a shell of D-alpha-tocopheryl polyethylene glycol 1,000 succinate (TPGS) and a core of ultrasound-responsive perfluorohexane, loaded with doxorubicin (DOX) were synthesized in this study to overcome these drawbacks. The encouraging results both in vitro and in vivo indicated that these original NDs exhibit excellent biocompatibility, targeting ability and therapeutic effects. TPGS not only acted as the shell material of NDs, but also had anti-cancer ability in itself. Furthermore, TPGS inhibited the activity of P-gp and thus simultaneously enhanced the sensitivity of DOX they carried. This work was the first to synthesize and report DOX-TPGS-NDs integrating synergistic strategies into a single nanodrug carrier. Our findings may provide scientific evidence to support the potential applications for reversing MDR.

Zitieren

APA

Ge, L., Liu, X., Sun, Y., Zhang, R., Liu, L., & Li, J. (2026). Targeted TPGS ultrasound-responsive nanodroplets modulate P-gp and mitochondria to enhance doxorubicin sensitivity in multidrug-resistant breast cancer. Frontiers in Bioengineering and Biotechnology, 14. https://doi.org/10.3389/fbioe.2026.1991867

Vancouver

Ge L, Liu X, Sun Y, Zhang R, Liu L, Li J. Targeted TPGS ultrasound-responsive nanodroplets modulate P-gp and mitochondria to enhance doxorubicin sensitivity in multidrug-resistant breast cancer. Frontiers in Bioengineering and Biotechnology. 2026;14. doi:10.3389/fbioe.2026.1991867

BibTeX
@article{Ge2026,
  author = {Ge, Ling and Liu, Xiaomeng and Sun, Yan and Zhang, Ruo and Liu, Limin and Li, Jie},
  title = {Targeted TPGS ultrasound-responsive nanodroplets modulate P-gp and mitochondria to enhance doxorubicin sensitivity in multidrug-resistant breast cancer},
  journal = {Frontiers in Bioengineering and Biotechnology},
  year = {2026},
  volume = {14},
  doi = {10.3389/fbioe.2026.1991867}
}
Kostenlos starten →